 COPENHAGEN, Denmark, April 06, 2021 GLOBE NEWSWIRE -- Evaxion Biotech AS Nasdaq: EVAX, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the fourth quarter and full year 2020 financial results and provided an operational update. 